Core Viewpoint - The National Medical Products Administration has approved the innovative drug Anlotinib (also known as Migalizumab) for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adults, which is expected to benefit more patients in China and improve their quality of life [1][2]. Group 1: Drug Approval and Mechanism - Anlotinib is a monoclonal antibody drug developed using biotechnology, specifically designed to block key inflammatory cytokines (IL-23p19 subunit) in the gut, thereby regulating excessive immune responses [1]. - The drug has already been approved in multiple countries and regions, including the US, Europe, and Japan, indicating its international recognition and potential effectiveness [1]. Group 2: Disease Impact and Patient Demographics - Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic and recurrent condition that has seen an increase in prevalence in China due to lifestyle changes, with Crohn's disease affecting approximately 3-4 cases per 100,000 people and ulcerative colitis affecting 17-18 cases per 100,000 people [1]. - The disease predominantly affects young adults, leading to symptoms such as abdominal pain, diarrhea, and weight loss, which significantly impact patients' quality of life and can result in increased healthcare costs, approximately three times higher than that of the general population [2]. Group 3: Clinical Efficacy - Clinical studies indicate that about one-third of patients treated with Anlotinib can observe early improvements in intestinal inflammation within three months, and nearly half can achieve clinical remission after one year of treatment, marking a promising new option for patients who have not responded well to traditional medications or other biologics [2].

Core Viewpoint - Fasting-mimicking diet (FMD) shows potential benefits in inducing clinical response, remission, and biochemical improvement in patients with mild to moderate Crohn's disease, outperforming standard dietary support [3][8]. Group 1: Fasting-Mimicking Diet (FMD) - FMD involves a 5-day low-calorie diet each month, designed to mimic fasting while ensuring essential nutrient intake, making it easier for individuals to adhere to [2]. - The study published in Nature Medicine indicates that FMD can significantly reduce inflammation and improve metabolic health in healthy individuals, but its effects on Crohn's disease were previously unstudied [7]. Group 2: Clinical Trial Findings - In a randomized controlled trial, 69.2% of patients in the FMD group achieved the primary outcome of a 70-point reduction in Crohn's Disease Activity Index (CDAI) compared to 43.8% in the control group [7]. - Secondary outcomes showed that 64.6% of the FMD group reached clinical remission, while only 37.5% of the control group did [7]. - FMD group exhibited a 22.0% decrease in fecal calprotectin levels, an inflammation marker, while the control group saw an 8.0% increase [7]. Group 3: Mechanistic Insights - Exploratory analyses revealed that FMD led to reductions in key inflammatory lipid mediators and immune response transcripts, correlating with decreased Crohn's disease activity [8].

Core Viewpoint - The study highlights the role of the oral symbiotic bacterium Veillonella in promoting Clostridioides difficile infection (CDI) in patients with Crohn's disease by inhibiting bile acid transport protein ASBT, leading to abnormal bile acid accumulation in the intestine [3][9]. Group 1: Disease Overview - Crohn's disease is a common inflammatory bowel disease (IBD) characterized by abdominal pain, diarrhea, and intestinal obstruction, affecting the entire digestive tract with a high postoperative recurrence rate of approximately 80% [2]. - The global prevalence of IBD was 0.75% as of 2020, projected to rise to 1.0% by 2030, with 37%-59% of IBD cases being Crohn's disease [2]. Group 2: Research Findings - The research published in Cell Host & Microbe indicates that Veillonella intestinal colonization promotes CDI in Crohn's disease patients [3]. - Veillonella parvula inhibits the expression of the bile acid transport protein ASBT, preventing bile acid reabsorption and causing abnormal bile acid accumulation in the intestine, which triggers CDI [9][12]. - The study found a correlation between the abundance of Veillonella and increased bile acid metabolism in Crohn's disease patients, suggesting that the presence of bile acids can facilitate the germination of C. difficile spores [9][12].

Core Insights - The article highlights the rising prevalence of Inflammatory Bowel Disease (IBD) in China, with current incidence rates ranging from 1.96 to 3.14 per 100,000 people, particularly affecting young adults [1] Misconceptions about IBD - Misconception 1: IBD is merely diarrhea; it includes Ulcerative Colitis (UC) and Crohn's Disease (CD), which are chronic inflammatory conditions affecting the gastrointestinal tract, with symptoms like abdominal pain, weight loss, and severe complications [2] - Misconception 2: IBD is a diet-related disease; while diet can influence symptoms, IBD is linked to genetic susceptibility and immune dysfunction, not directly caused by food [3] - Misconception 3: IBD patients cannot marry or have children; while there is a hereditary risk, many IBD patients successfully have healthy pregnancies with proper medical management [4] - Misconception 4: IBD requires long-term maintenance therapy; abrupt discontinuation of medication can lead to rebound inflammation, with studies showing a 60% five-year remission rate with regular treatment [5] - Misconception 5: IBD inevitably leads to cancer; while uncontrolled inflammation increases cancer risk, regular monitoring and treatment can mitigate this risk [6] - Misconception 6: Surgery can cure IBD; surgery is only for complications and does not eliminate the disease, with a high recurrence rate post-surgery [7] - Misconception 7: IBD patients should avoid exercise; moderate exercise can improve gut motility and quality of life, with recommendations for low-intensity activities [8] - Misconception 8: IBD can only be managed with Western medicine; a combination of Western and alternative therapies can provide a personalized treatment approach [9] - Misconception 9: IBD is an incurable disease; it is now considered a manageable chronic condition, with over 80% clinical remission rates achievable through proper treatment [10] Research and Development - Global research on IBD is advancing rapidly, with innovative treatments like fecal microbiota transplantation and CAR-T cell therapy entering clinical trials in China, potentially leading to breakthroughs in the next decade [11] - The focus is shifting towards precision diagnosis, individualized treatment, and accelerated drug development, aiming for a future where patients can coexist peacefully with IBD [12]